POINT Biopharma Posts New Preclinical Data, Exercises Option For FAP Inhibitor
Point Biopharma Global Inc (NASDAQ:PNT) has additional preclinical data from its fibroblast activation protein-alpha (FAP-alpha) inhibitor program, PNT2004. The new data…